alexa Role of Novel Oral Anticoagulants in Primary and Second
ISSN: 2329-8790

Journal of Hematology & Thromboembolic Diseases
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Role of Novel Oral Anticoagulants in Primary and Secondary Thromboprophylaxis in Cancer

Elizabeth Bowhay-Carnes*, Anand Karnad, Subrata Haldar, John Sarantopoulos and Sumit Madan
Cancer Therapy and Research Center, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, 78229-3900, USA
Corresponding Author : Elizabeth Ann Bowhay-Carnes
Cancer Therapy and Research Center
The University of Texas Health Science Center at San Antonio
Department of Medicine
7979 Wurzbach Rd, San Antonio
Texas 78229, USA
Tel: 1-210-315-3878
E-mail: [email protected]
Received: August 27, 2015 Accepted: October 27, 2015 Published: November 03, 2015
Citation: Carnes EB, Karnad A, Haldar S, Sarantopoulos J, Madan S (2015) Role of Novel Oral Anticoagulants in Primary and Secondary Thromboprophylaxis in Cancer. J Hematol Thrombo Dis 3:222. doi:10.4172/2329-8790.1000222
Copyright: © 2015 Carnes EB, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at Pubmed, Scholar Google


The development of venous thromboembolism is one of the major causes of morbidity and mortality in patients with cancer. The standard treatment of deep venous thrombosis or pulmonary embolism occurring in patients with active malignancy remains the use of low molecular weight heparins. However, in clinical practice, practitioners are frequently asked about the efficacy and safety of various new oral anticoagulants in cancer patients. In the United States, there are currently 4 different novel oral anticoagulants commercially available with the indication of the treatment of acute venous thromboembolism. These include dabigatran (Pradaxa), rivaroxaban (Xarelto), apixaban (Eliquis), and edoxaban (Savaysa). Use of these new medications is appealing due to the ease of administration, avoidance of injections, ability to use in patients with decreased renal or liver function, and consistent efficacy without fooddrug interactions. Currently, the only available data for the use of these new oral anticoagulants in cancer patients is from subgroup analysis of larger studies with no statistical significance. However, this preliminary data is encouraging that the novel oral anticoagulants may be effective and safe for primary and secondary prevention of venous thromboembolism in cancer patients. Further clinical trials are greatly needed for the head-tohead comparison of these novel oral anticoagulants versus low molecular weight heparins. Although the routine use of novel oral anticoagulants for the prevention or treatment of venous thromboembolism in cancer patients cannot be recommended at this time, we strongly support the development of Phase III trials assessing their efficacy and safety in patients with active malignancies compared to the current standard of care treatment with low molecular weight heparin.


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version